GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scandion Oncology A/S (OSTO:SCOL) » Definitions » Institutional Ownership

Scandion Oncology A/S (OSTO:SCOL) Institutional Ownership : 0.01% (As of Jun. 07, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Scandion Oncology A/S Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Scandion Oncology A/S's institutional ownership is 0.01%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Scandion Oncology A/S's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Scandion Oncology A/S's Float Percentage Of Total Shares Outstanding is 0.00%.


Scandion Oncology A/S Institutional Ownership Historical Data

The historical data trend for Scandion Oncology A/S's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scandion Oncology A/S Institutional Ownership Chart

Scandion Oncology A/S Historical Data

The historical data trend for Scandion Oncology A/S can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01

Scandion Oncology A/S Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Scandion Oncology A/S (OSTO:SCOL) Business Description

Traded in Other Exchanges
Address
Fruebjergvej 3, Symbion, Copenhagen, DNK, 2100
Scandion Oncology A/S is a clinical-stage biotechnology company developing first-in-class medicines aimed at treating cancer that is resistant to current treatment options. Cancer Drug Resistance Company discovers and develops first-in-class medicines aimed at treating cancer that is resistant to current treatment options.

Scandion Oncology A/S (OSTO:SCOL) Headlines

No Headlines